Bioavailability and Bioequivalence: An FDA Regulatory Overview
- 1 January 2001
- journal article
- review article
- Published by Springer Science and Business Media LLC in Pharmaceutical Research
- Vol. 18 (12), 1645-1650
- https://doi.org/10.1023/a:1013319408893
Abstract
Bioavailability and/or bioequivalence studies play a key role in the drug development period for both new drug products and their generic equivalents. For both, these studies are also important in...Keywords
This publication has 11 references indexed in Scilit:
- Measures of Exposure versus Measures of Rate and Extent of AbsorptionClinical Pharmacokinetics, 2001
- An individual bioequivalence criterion: regulatory considerationsStatistics in Medicine, 2000
- Where are we now and where do we go next in terms of the scientific basis for regulation on bioavailability and bioequivalence?European Journal of Drug Metabolism and Pharmacokinetics, 2000
- Evaluation of bioequivalence of highly variable drugs using clinical trial simulations. II: Comparison of single and multiple-dose trials using AUC and Cmax.Pharmaceutical Research, 1998
- Absorption Rate Vs. Exposure: Which Is More Useful for Bioequivalence Testing?Pharmaceutical Research, 1996
- A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo BioavailabilityPharmaceutical Research, 1995
- Evaluation of Bioequivalence of Highly Variable Drugs Using Monte Carlo Simulations. I. Estimation of Rate of Absorption for Single and Multiple Dose Trials Using CmaxPharmaceutical Research, 1995
- Comparison of Single and Multiple Dose Pharmacokinetics Using Clinical Bioequivalence Data and Monte Carlo SimulationsPharmaceutical Research, 1994
- Standardized challenge testing with pharmacological, physical and sensitizing stimuli in adultsEuropean Respiratory Journal, 1993
- Understanding the Dose-Effect RelationshipClinical Pharmacokinetics, 1981